QuidelOrtho Corporation completed the acquisition of UK‑based molecular diagnostics company LEX Diagnostics on April 20, 2026, for approximately $100 million in cash. The deal brings LEX’s VELO system, an ultra‑fast RT‑PCR platform that delivers multiplex results for influenza A, influenza B and COVID‑19 in six to ten minutes, into QuidelOrtho’s product lineup.
The VELO system received FDA 510(k) clearance and a CLIA waiver in February 2026, positioning it as a lab‑quality, point‑of‑care solution that eliminates the need for external liquid handling. Its proprietary cartridge design simplifies workflow and reduces turnaround time, making it attractive for urgent‑care centers and physician offices.
QuidelOrtho’s recent financials illustrate the context for the acquisition. In Q4 2025 the company reported an adjusted EPS of $0.46, below the $0.51 forecast, while revenue of $724 million exceeded expectations. In Q1 2025 revenue was $693 million versus $711 million a year earlier, and adjusted diluted EPS rose to $0.74 from $0.44. The company has guided 2026 revenue to $615–$620 million, below the consensus estimate of $679.59 million, reflecting a weaker respiratory season and regional disruptions. Management expects the transaction to be margin‑dilutive in 2026 but accretive in 2027–2028 as the VELO platform gains market traction.
Strategically, the acquisition marks a pivot away from the Savanna platform and a focus on the high‑growth point‑of‑care molecular diagnostics market. Industry forecasts project the market to grow from $15.78 billion in 2025 to $23.62 billion by 2034, a CAGR of 4.71%. By adding the VELO system, QuidelOrtho aims to strengthen its position in this expanding segment and provide a new growth engine that complements its existing immunoassay, clinical chemistry and transfusion medicine businesses.
Brian J. Blaser, President and CEO of QuidelOrtho, said, "The FDA clearance of the LEX VELO System and the completion of our acquisition of LEX mark a pivotal moment for QuidelOrtho and for our customers. This ultra‑fast PCR platform is designed to deliver lab‑quality results in minutes and fits seamlessly into point‑of‑care workflows. It empowers providers to act faster, make better‑informed decisions and ultimately improve patient outcomes." Ed Farrell, CEO of LEX Diagnostics, added, "LEX achieved an extraordinary milestone with FDA clearance and CLIA waiver of the LEX VELO System. We are proud to join QuidelOrtho and to bring this technology to customers worldwide. We believe we can redefine what is possible in point‑of‑care molecular diagnostics."
The acquisition occurs amid near‑term headwinds, including a weaker respiratory season and regional disruptions that have pressured QuidelOrtho’s revenue guidance. Analysts have noted that the company’s strategic shift and the addition of the VELO platform position it for long‑term growth, even as short‑term financial performance remains challenged by market conditions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.